24/7 Market News Snapshot 26 February, 2025 – AIM ImmunoTech Inc. (NYSE:AIM)

February 26, 2025

DENVER, Colo., 26 February, 2025 (247marketnews.com) – (NYSE:AIM) are discussed in this article.
AIM ImmunoTech Inc. has recently experienced a significant uptick in market performance, opening today at $0.113 and currently trading at $0.135, representing a notable increase of approximately 8.96%. This upward trend follows the previous session’s close at $0.124, suggesting a robust bullish sentiment. With a trading volume of 5.07 million shares, investor interest remains strong. Technical analysis indicates a potential continuation of this trend, as the stock nears key resistance levels; thus, traders should keep an eye out for breakout confirmations and volume trends that could signal further investment opportunities.

In a noteworthy development, AIM ImmunoTech has received approval from the NYSE American for its Plan to regain compliance with minimum stockholders’ equity requirements. This acceptance marks a critical milestone in AIM’s commitment to meet the standards necessary for continued listing. The company has until June 11, 2026, to fulfill compliance criteria as stipulated in Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide.

CEO Thomas K. Equels expressed optimism about this approval, thanking the NYSE American for their support and reiterating the company’s dedication to executing its strategic plan in the months to come. AIM remains focused on advancing its oncology and antiviral pipelines, particularly through its lead investigational drug, Ampligen® (rintatolimod), known for its dual-strand RNA functionality that acts as a selective TLR3 agonist. This innovative approach aims to tackle a range of health challenges, from various cancers to viral diseases, including COVID-19.

As AIM ImmunoTech continues to progress, it stays dedicated to the advancement of immunotherapy and maintaining operational integrity, signifying its role as a pivotal entity in the immuno-pharmaceutical arena. Stakeholders are encouraged to follow ongoing developments as the company champions groundbreaking therapeutic solutions.

Related news for (AIM)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.